Clinical Trial Update: Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating oblimersen sodium in combination with rituximab for recurrent B-cell non-Hodgkin lymphoma completed, with results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous B-cell Non-hodgkin Lymphoma
• Diffuse Large B-cell Lymphoma
• Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Small Lymphocytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Genasense (oblimersen)
• Rituxan (rituximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 2 | Status: COMPLETED | Results posted: 2011-02-21